Abstract:Objective To investigate the efficacy of Ateppase thrombolysis in the treatment of acute cerebral infarction (ACI) and the risk factors of neurological deterioration in the time window.Methods From August 2016 to December 2017, 143 patients with acute cerebral infarction were selected as the subjects. The sex, age, body mass index, personal history, complications, pre-treatment NIHSS score, and onset to thrombolysis time were collected. Baseline blood pressure, blood glucose, and low density lipoprotein (LDL) levels were observed. The correlation of the above indexes with prognosis and thrombolytic outcome were observed.Results Among the 143 patients, 84 had good outcomes, accounting for 58.74%, and 59 patients with poor outcomes, accounting for 41.26%. Univariate analysis showed no significant differences in drinking, history of atrial fibrillation, baseline systolic blood pressure, and baseline diastolic blood pressure (P > 0.05). There were statistically significant differences in gender, age, body mass index, smoking, onset to thrombolytic time, hypertension, diabetes, hyperlipidemia, baseline NIHSS score, baseline blood glucose, and baseline low density lipoprotein (P < 0.05). Time from onset to thrombolysis [R = 4.274 (95% CI: 2.085, 8.169)], baseline NIHSS score [R = 1.459 (95% CI: 1.238, 2.054)], baseline blood glucose [R = 1.794 (95% CI: 1.317, 2.576)], and toxic low-density lipoprotein [R = 2.246 (95% CI: 1.872, 3.417)] are risk factors that lead to poor thrombolytic outcomes (P < 0.05).Conclusion The time from onset to thrombolysis, baseline NIHSS score, baseline blood glucose, and baseline low-density lipoprotein are independent risk factors that lead to poor thrombolytic outcome. Clinically, these factors should be considered comprehensively before clinical thrombolysis of patients with acute cerebral infarction and focused to make interventions to improve the prognosis of intravenous thrombolysis.